The study of pyrazinamide resistance in Mycobacterium tuberculosis isolates from high-risk groups at Office of Disease Prevention and Control 3 Nakhonsawan between fiscal year 2016 to 2018

Authors

  • Veeralak Saytangjai B.S. (Medical Technology) Office of Disease Prevention and Control Nakhon Sawan Province Region 3
  • Sommawan Kaewsangthongcharoen B.S. (Medical Technology) Office of Disease Prevention and Control Nakhon Sawan Province Region 3
  • Anugoon Bunkhong B.S. (Medical Technology), LL.B., M.MT. Office of Disease Prevention and Control Nakhon Sawan Province Region 3

Keywords:

Pyrazinamide, Multidrug-resistant tuberculosis (MDR-TB), High risk group

Abstract

This study aimed to determine the rate of PZA resistance in three high-risk groups of tuberculosis (TB) patients consists of re-treatment, on-treatment and pre-treatment. Three hundred and seventy-one of high-risk group samples were performed using drug susceptibility testing in tuberculosis laboratory of the Office of Disease Prevention and Control 3 NakhonSawan Province, during fiscal year 2016 to 2018. The highest rate of PZA resistance was the on-treatment group (15.9%) followed by re-treatment group (11.0%) and pre-treatment group (8.2%), respectively but there were no statistically significant differences (P-value = 0.186). The rates of PZA resistance were found in 32.4% of MDR-TB isolates and 6.6% of pan-susceptible isolates. Comparison of drug susceptibility testing results of PZA and other four first-line anti-tuberculosis drugs i.e., streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB) showed statistically significant differences (P-value <0.05). The highest rate of PZA resistance was 80.0% that found in EMB resistance isolates while PZA resistance rates of RIF, SM and INH resistance isolates were 28.9%, 28.6% and 27.4%, respectively. PZA susceptibility testing should be performed in three high-risk groups especially on-treatment group because percentage of MDR-TB and the PZA resistance rate of this group were high.

References

World Health Organization. Global tuberculo-sis report 2019. Geneva, Switzerland: WHO; 2019.

World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva, Switzerland: WHO; 2017.

สำนักวัณโรค กรมควบคุมโรค. แนวทางการรักษาผู้ป่ วยวัณโรคดื้อยาหลายขนาน ด้วยสูตรยาระยะสั้น 9 เดือน. กรุงเทพฯ: สำนักพิมพ์อักษรกราฟฟิ คแอนด์ดีไซน์; 2561.

สำนักวัณโรค กรมควบคุมโรค. แนวทางการบริหารจัดการผู้ป่ วยวัณโรคดื้อยา. กรุงเทพฯ: โรงพิมพ์ชุมนุมสหกรณ์การเกษตรแห่งประเทศไทย; 2558.

World Health Organization. WHO consolidat-ed guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: WHO; 2019.

Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, et al.My-cobacterium tuberculosis pyrazinamide resis-tance determinants: a multicenter study. mBio 2014;5(5):e01819-14.

Aung WW, Ei PW, Nyunt WW, Htwe MM, Win SM, Aye KT, et al. Pyrazinamide resis-tance among multidrug-resistant Mycobacte-rium tuberculosis clinical isolates in Myanmar. Antimicrob Agents Chemother 2018;62:e01984-17.

Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, et al. Pyrazinamide resistance among South African multidrug-resistant My-cobacterium tuberculosisisolates. J Clin Mi-crobiol 2008;46(10):3459-64.

Ando H, Mitarai S, Kondo Y, Suetake T, Seki-guchi JI, Kato S, et al. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuber-culosis isolates in Japan. Clin Microbiol Infect 2010;16(8):1164-8.

Jonmalung J, Prammananan T, Leechaweng-wongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multi-drug-resistant Mycobacterium tuberculosisisolates from Siriraj Hospital, Thailand. BMC Microbiol 2010;10:223.

Fonseca Lde S, Marsico AG, Vieira GB, Duarte Rda S, Saad MH, Mello Fde C. Cor-relation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolat-ed at a referral hospital. J Bras Pneumol 2012;38(5):630-3.

Tola HH, Tol A, Shojaeizadeh D, Garma-roudi G. Tuberculosis Treatment Non-Ad-herence and Lost to Follow Up among TB Patients with or without HIV in Developing Countries: A Systematic Review. Iran J Pub-lic Health 2015;44(1):1-11.

Downloads

Published

13-01-2021

How to Cite

1.
Saytangjai B.S. (Medical Technology) V, Kaewsangthongcharoen B.S. (Medical Technology) S, Bunkhong B.S. (Medical Technology), LL.B., M.MT. A. The study of pyrazinamide resistance in Mycobacterium tuberculosis isolates from high-risk groups at Office of Disease Prevention and Control 3 Nakhonsawan between fiscal year 2016 to 2018. JDPC3 [internet]. 2021 Jan. 13 [cited 2025 Dec. 17];14(3):56-68. available from: https://he01.tci-thaijo.org/index.php/JDPC3/article/view/244452

Issue

Vol. 14 No. 3 (2020): September - December

Section

Original Article

License

Copyright (c) 2020 Journal of Disease and Health Risk DPC.3

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright notice

Article published in the Journal of Disease and Health Risk DPC.3 Nakhon Sawan. It is considered a work of academic research and analysis as well as the personal opinion of the author. It is not the opinion of the Office of Disease Prevention and Control 3,    Nakhon Sawan. Or the editorial team in any way Authors are responsible for their articles.

 

Privacy Policy

Name, address and e-mail address specified in the Journal of Disease and Health Risk DPC.3 Nakhon Sawan. It is used for identification purposes of the journal. And will not be used for any other purpose. Or to another person.